Detection of minimal residual disease (MRD) has become a strong diagnostic tool in acute leukemia. In acute lymphoblastic leukemia, it is widely used for risk-adapted therapy. In acute myeloid leukemia (AML), it is still a matter of debate how best to measure MRD. A number of different methods are competing. 1, 2 In the comparison of these methods, it has become common practice to advertise the high sensitivity of one or the other method. In this context, sensitivity usually means the lowest proportion of leukemic cells that can be measured. Unfortunately, this type of sensitivity is not only a technically incorrect use of the word, but also information with very limited relevance. The crucial point is not the lowest proportion of leukemic cells that is measurable, but the lowest proportion of leukemic cells that are clearly distinguishable from any healthy or, even more importantly, any leukemia-free, regenerating bone marrow. Here we discuss the importance of these differences and the consequences for comparing different methods of detecting MRD.
The sensitivity of a diagnostic test is defined as the likelihood of a positive test result in a truly positive patient. This definition is only applicable to tests with dichotomous results. Measurement of MRD gives continuous results, but cutoffs are defined for clinical decision-making. Therefore, patients are classified in a dichotomous manner as high-MRD (above the threshold) or low-MRD (below the threshold).
In this setting, different methods of monitoring MRD can be compared using the terms sensitivity and specificity. The sensitivity is the likelihood of classifying patients as high MRD if the percentage of leukemic cells in their bone marrow is really higher than the threshold. The specificity of the method is the likelihood of classifying patients as low MRD if the percentage of leukemic cells in their bone marrow is really lower than the threshold.
Both sensitivity and specificity strongly depend on the threshold that is used. For different clinical questions, different thresholds could be relevant. Therefore, it is meaningless to talk about the sensitivity or the specificity of monitoring MRD without defining the threshold that one is interested in.
Another important issue is that sensitivity and specificity of detecting MRD vary from patient to patient. They depend on the copy numbers of the leukemia-associated genes (WT1, PRAME and others [3] [4] [5] ) that are used for PCR or the quality of the leukemiaassociated phenotypes that are used for flow cytometry. 6 Therefore, any statement on the quality of a method of monitoring MRD should include the following data: the threshold that is used for clinical decision-making, sensitivity, specificity and the proportion of patients for whom this level of quality can be achieved. For instance, the statement could be: At a threshold of 1 leukemic cell in 1000 healthy bone marrow cells, this method allows one to measure MRD with a sensitivity X80% and a specificity X90 in 70% of all AML patients.
Throughout the literature on MRD, it is difficult to find any paper that includes this complete set of information. The main problem is that we do not have a gold standard for the monitoring of MRD.
In papers about MRD, the term sensitivity is often used in a completely different way. It is used to describe the lowest proportion of leukemic cells that gives a positive test result.
A commonly performed experiment to determine this type of sensitivity is to establish serial dilution of leukemic cells in a sample of healthy bone marrow. The healthy bone marrow that is selected for this experiment is usually completely negative for the MRD marker. The lowest proportion of leukemic cells, which still gives a positive test result, is then called the sensitivity of the test.
A better term for this type of sensitivity would be lowest possible threshold (LPT) because it is not the sensitivity of the diagnostic test (likelihood of a positive test result in a truly positive patient).
These experiments provide useful information only if the test is 100% specific for leukemic cells, that is, if every healthy bone marrow gives completely negative result.
Real-time PCR for immunoglobulin rearrangements (acute lymphoblastic leukemia) 7 or specific mutations (AML) 1,2 are highly specific methods of measuring MRD. Flow cytometry or real-time PCR for leukemia-associated genes (WT1, PRAME and others) always give a certain amount of positivity in leukemiafree samples (Lapillone et al.; 3 Instead, we look at bone marrows that are regenerating after heavy chemotherapy. The expression of presumed leukemiaspecific genes or the frequency of presumed leukemia specific phenotypes can be very different in such samples compared to steady-state healthy bone marrow.
For instance, the gene CSPG4 was identified as a possible MRD marker. 4 It was highly expressed in AML samples but not in healthy bone marrow. However, we found that it was useless as an MRD marker because expression of CSPG4 was also high in bone marrow that was free of leukemia but was regenerating after chemotherapy. 4 Therefore, to determine the real sensitivity and specificity of an MRD analysis, it is mandatory to analyze a large number of leukemia-free, regenerating bone marrows.
A second problem of analyzing serial dilutions of leukemic cells in samples of healthy bone marrow is that this does not really simulate the situation of minimal residual disease. The important clinical question is the amount of leukemic stem cells that is still present in the patient. If the leukemic phenotype that is used for flow cytometry is present on the majority of leukemic cells but not on leukemic stem cells, the sensitivity could be lower than anticipated. If the expression of a leukemia-associated gene, like WT1, is particularly high in leukemic stem cells, the sensitivity might be much better than anticipated and vice versa.
Conclusions
Monitoring MRD has become a strong diagnostic tool in acute leukemia. It is widely used for clinical decision-making in acute lymphoblastic leukemia, chronic myeloid leukemia and acute promyelocytic leukemia. Various methods have been developed to monitor MRD in AML and we should proceed to put them into clinical practice.
Sensitivity is an important issue in the comparison of these methods. When the term is used, it should always be clear whether we are talking about the LPT or the real sensitivity and specificity of our diagnostic test.
The LPT is easy to determine and for most methods of monitoring MRD, is in the range of 10 À4 -10 À6 . These figures have a very limited meaning because for clinical decisionmaking LPT cannot be used as the cutoff for high versus low MRD. At such a low threshold, the specificity of monitoring MRD (likelihood of a negative test result in a truly negative patient) is too low due to false positive healthy and regenerating bone marrows.
If we use, for instance, a threshold of 10 À3 for clinical decision-making, it does not matter whether the LPT is 10 À4 or 10 À6 . What really matters is the sensitivity and specificity of the diagnostic test at the threshold of 10 À3 . We should put less effort into determining LPTs and more effort into determining sensitivity and specificity of our methods at the clinically relevant thresholds.
Because of the many issues that influence the quality of each method of monitoring MRD, the best way of really comparing two methods is to simultaneously apply both of them in one clinical trial. Such studies are strongly needed. ETV6 (ETS translocation-variant gene 6, located on chromosome 12p), also known as TEL, encodes a transcription repressor belonging to the E26 transforming specific (ETS) family of DNAbinding proteins. ETV6 is known as a proto-oncogene involved in translocation with over 40 partners. 1 In acute myeloid leukemia (AML) only a few rare translocations result in transforming fusion proteins, 1 indicating that the oncogenic role of ETV6 does not play a major part in AML. However, abnormalities of the short
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